Pioneer Surgical Technology has received 510(k) FDA clearance to market FortrOss, a novel bone graft substitute utilising the power of nanotechnology for orthopaedic applications. The FortrOss bone void filler is a scaffold for the in-growth of new bone and other connective tissues, when superior bone regeneration is required.
“The FortrOss carrier is a collagen based bioscaffold processed to provide an osteopromotive effect. Pioneer’s patented E-Matrix technology provides the unique open structure for bone growth and repair,” said Dr Ron Hill, Vice President of Research and Development.
The osteoconductive matrix in FortrOss utilises Pioneer’s nanOss technology and is designed to mimic the nanostructures inherent in boney tissue. Dr Edward Ahn, Vice President of Biomaterials stated, “Because the nanOss hydroxyapatite in FortrOss resembles the size, shape, and chemistry of native bone, boney tissue has a great affinity for nanOss and recognizes it as native tissue. This mimicry of native bone makes nanOss superior to other calcium phosphates on the market.” FortrOss is expected to be launched on the US market released later this year.
